Literature DB >> 20082651

Pearls for ablation in congenital heart disease.

Ronald J Kanter1.   

Abstract

Tachyarrhythmias occur in patients having congenital heart disease most commonly related to surgically created or naturally occurring conduction obstacles, and to postoperative hemodynamic effects on cardiac muscle. Less frequently, the underlying disease is associated with tachycardia substrates. Thorough knowledge of the patient's congenital anatomy and surgical procedures is required before considering catheter ablation. In many instances, procedural considerations should include meticulous hemodynamic surveillance, analogous to patients having structurally normal heart but cardiomyopathy. This includes careful selection of sedating and anesthetic agents. Congenital heart defects that have a higher than expected incidence of naturally occurring tachyarrhythmia substrates include Ebstein anomaly of the tricuspid valve, congenitally corrected transposition, and some of the heterotaxies. Intraatrial reentry tachycardia and atrial flutter are especially prevalent following the Mustard or Senning operations for d-transposition of the great arteries and the earlier Fontan type operations. Although these tachyarrhythmias are not as frequent following atrial septal defect repair, the high incidence of this defect also makes these patients germaine to this discussion. Focal atrial tachyacrdia and atrioventricular nodal reentry tachycardia also occur in these patient groups. Macroreentry ventricular tachycardia occurs most frequently following right ventricular outflow tract surgery, especially following repair of tetralogy of Fallot. This article focuses on the technical aspects of catheter ablation of these arrhythmias, due to the challenges presented by the underlying anatomy compared with patients having normal hearts.

Entities:  

Mesh:

Year:  2010        PMID: 20082651     DOI: 10.1111/j.1540-8167.2009.01685.x

Source DB:  PubMed          Journal:  J Cardiovasc Electrophysiol        ISSN: 1045-3873


  8 in total

1.  Factors associated with the occurrence and treatment of supraventricular tachycardia in a pediatric congenital heart disease cohort.

Authors:  Avnish Tripathi; George B Black; Yong-Moon Mark Park; Jeanette M Jerrell
Journal:  Pediatr Cardiol       Date:  2013-09-01       Impact factor: 1.655

Review 2.  Maximizing the Effectiveness of Ablation for Arrhythmias in the Congenital Heart Patients.

Authors:  Aruna Arujuna; Joseph de Bono
Journal:  Curr Cardiol Rep       Date:  2016-07       Impact factor: 2.931

Review 3.  [Congenital heart defects in adulthood : Supraventricular tachycardia].

Authors:  J Hebe
Journal:  Herzschrittmacherther Elektrophysiol       Date:  2016-05-25

4.  Ablation of Arrhythmias in Patients with Adult Congenital Heart Disease.

Authors:  Rodrigo Gallardo Lobo; Michael Griffith; Joseph De Bono
Journal:  Arrhythm Electrophysiol Rev       Date:  2014-05-18

5.  [Interventional treatment of tachyarrhythmia in children with congenital heart disease].

Authors:  Joachim Hebe; Jan-Hendrik Nürnberg; Klaus Langes
Journal:  Herzschrittmacherther Elektrophysiol       Date:  2014-09

6.  Successful ablation of two right atrial tachycardias on either side of the lateral tunnel patch in a patient with double inlet left ventricle and total cavopulmonary connection: Two sites and two mechanisms.

Authors:  Sabine Ernst; Michala Pedersen; Anselm Uebing; Irina Suman-Horduna; Lilian Mantziari; Wei Li; Sonya V Babu-Narayan
Journal:  Glob Cardiol Sci Pract       Date:  2013-11-01

7.  Catheter ablation of manifest posteroseptal accessory pathway associated with coronary sinus diverticula in a child with congenitally corrected transposition of the great arteries.

Authors:  Yakup Ergül; Osman Esen; Senem Özgür; Alper Güzeltaş
Journal:  Anatol J Cardiol       Date:  2018-02       Impact factor: 1.596

8.  Missing pouches in high-density mapping of atrial tachyarrhythmia in congenital heart diseases.

Authors:  Sit-Yee Kwok; Tak-Cheung Yung; Ngai-Lun Ho; Jo-Jo Hai; Sabrina Tsao; Hung-Fat Tse
Journal:  J Arrhythm       Date:  2019-10-23
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.